Physician profile
Eric Bentolila
NPI 1487726675
$369.91
in general payments reported to CMS, 2019-2025
16 companies · $55.11 in 2025
The $55.11 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $24.48 · 2022: $96.77 · 2023: $30.79 · 2024: $57.70 · 2025: $55.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $143.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $58.57 | 2022-2023 | |
| Myovant Sciences INC. | $39.89 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.76 | 2019-2025 | |
| Millicent US INC | $30.15 | 2025 | Femlyv, Intrarosa |
| Agile Therapeutics, INC. | $29.16 | 2022-2024 | Twirla |
| Hologic Sales and Service, LLC | $28.48 | 2020-2022 | |
| Vertical Pharmaceuticals, LLC | $27.45 | 2019 | |
| Allergan, INC. | $25.48 | 2019 | |
| Amag Pharmaceuticals, INC. | $16.37 | 2019 | |
| Coopersurgical, INC. | $15.66 | 2024 | Paragard T 380a |
| Exeltis, USA INC. | $15.62 | 2024 | Slynd |
| Duchesnay USA Incorporated | $12.55 | 2019 | |
| Mission Pharmacal Company | $11.41 | 2019 | |
| Aspira Women'S Health INC | $11.40 | 2020 | |
| Organon LLC | $10.96 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Bentolila listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.